Research & Development
Antengene and partners announces selinexor as potential therapeutic strategy for COVID-19 based on published preclinical data
26 July 2021 -

Biopharmaceutical company Antengene Corporation Limited said on Sunday that the results from a preclinical study jointly conducted with Karyopharm Therapeutics and University of Georgia College of Veterinary Medicine has been published in a paper titled "selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo."

Published in Antiviral Research, which is a scientific journal in virology, the study showed that the nuclear export protein exportin-1 (XPO1) plays a direct role in severe acute respiratory syndrome coronavirus 2 infections and the pathogenesis of coronavirus disease 19 and the selective oral inhibitor of XPO1, selinexor, has potent anti-SARS-CoV-2 activity both in vitro and in vivo, added the partnership.

Based on the results from this study and other existing evidence, XPO1 has a direct role in SARS-CoV replication and pathogenesis and is responsible for the nuclear export of certain SARS-CoV proteins that evades innate immunity, revealed the company.

The partners disclosed selinexor inhibits inflammatory cytokine expression by lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear cells (PBMCs). Elevated level of inflammatory cytokine is a key etiological feature and cause of death in patients infected with SARS-CoV-2. The selinexor can significantly lower the ex vivo inflammatory cytokine release by LPS-stimulated human PBMCs.

In addition, Selinexor is the first and only oral SINE compound approved by the FDA and is the first drug approved for the treatment of both MM and DLBCL, concluded the company.



Related Headlines